Cargando…

Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?

OBJECTIVES: To determine whether the halo count (HC) on temporal and axillary artery US (TAUS) predicts time to relapse in giant cell arteritis (GCA). METHODS: We conducted a single-centre retrospective study of GCA patients. HC, the number of vessels with non-compressible halo on the TAUS at diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Esperança Almeida, Diogo, Smith, Kate, Sarker, Borsha A, Barr, Andrew, Wakefield, Richard J, Mackie, Sarah L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629793/
https://www.ncbi.nlm.nih.gov/pubmed/37137277
http://dx.doi.org/10.1093/rheumatology/kead179
_version_ 1785132029276323840
author Esperança Almeida, Diogo
Smith, Kate
Sarker, Borsha A
Barr, Andrew
Wakefield, Richard J
Mackie, Sarah L
author_facet Esperança Almeida, Diogo
Smith, Kate
Sarker, Borsha A
Barr, Andrew
Wakefield, Richard J
Mackie, Sarah L
author_sort Esperança Almeida, Diogo
collection PubMed
description OBJECTIVES: To determine whether the halo count (HC) on temporal and axillary artery US (TAUS) predicts time to relapse in giant cell arteritis (GCA). METHODS: We conducted a single-centre retrospective study of GCA patients. HC, the number of vessels with non-compressible halo on the TAUS at diagnosis, was determined by retrospective review of the US report and images. Relapse was defined as increase in GCA disease activity requiring treatment escalation. Cox proportional hazard regression was used to identify predictors of time to relapse. RESULTS: A total of 72 patients with confirmed GCA were followed up for a median of 20.9 months. Thirty-seven of 72 (51.4%) relapsed during follow-up, at a median prednisolone dose of 9 mg (range 0–40 mg). Large-vessel (axillary artery) involvement did not predict relapse. On univariable analysis, a higher HC was associated with shorter time to relapse (per-halo hazard ratio 1.15, 95% CI 1.02, 1.30; P = 0.028). However, statistical significance was lost when the 10 GCA patients with an HC of zero were excluded from analysis. CONCLUSION: In this real-world setting, relapse occurred at a wide range of glucocorticoid doses and was not predicted by axillary artery involvement. GCA patients with a higher HC at diagnosis were significantly more likely to relapse, but significance was lost on excluding those with HC of zero. HC is feasible in routine care and may be worth incorporating into future prognostic scores. Further research is required to determine whether confirmed GCA patients with negative TAUS represent a qualitatively different subphenotype within the GCA disease spectrum.
format Online
Article
Text
id pubmed-10629793
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106297932023-11-08 Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis? Esperança Almeida, Diogo Smith, Kate Sarker, Borsha A Barr, Andrew Wakefield, Richard J Mackie, Sarah L Rheumatology (Oxford) Clinical Science OBJECTIVES: To determine whether the halo count (HC) on temporal and axillary artery US (TAUS) predicts time to relapse in giant cell arteritis (GCA). METHODS: We conducted a single-centre retrospective study of GCA patients. HC, the number of vessels with non-compressible halo on the TAUS at diagnosis, was determined by retrospective review of the US report and images. Relapse was defined as increase in GCA disease activity requiring treatment escalation. Cox proportional hazard regression was used to identify predictors of time to relapse. RESULTS: A total of 72 patients with confirmed GCA were followed up for a median of 20.9 months. Thirty-seven of 72 (51.4%) relapsed during follow-up, at a median prednisolone dose of 9 mg (range 0–40 mg). Large-vessel (axillary artery) involvement did not predict relapse. On univariable analysis, a higher HC was associated with shorter time to relapse (per-halo hazard ratio 1.15, 95% CI 1.02, 1.30; P = 0.028). However, statistical significance was lost when the 10 GCA patients with an HC of zero were excluded from analysis. CONCLUSION: In this real-world setting, relapse occurred at a wide range of glucocorticoid doses and was not predicted by axillary artery involvement. GCA patients with a higher HC at diagnosis were significantly more likely to relapse, but significance was lost on excluding those with HC of zero. HC is feasible in routine care and may be worth incorporating into future prognostic scores. Further research is required to determine whether confirmed GCA patients with negative TAUS represent a qualitatively different subphenotype within the GCA disease spectrum. Oxford University Press 2023-05-03 /pmc/articles/PMC10629793/ /pubmed/37137277 http://dx.doi.org/10.1093/rheumatology/kead179 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Esperança Almeida, Diogo
Smith, Kate
Sarker, Borsha A
Barr, Andrew
Wakefield, Richard J
Mackie, Sarah L
Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
title Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
title_full Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
title_fullStr Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
title_full_unstemmed Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
title_short Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
title_sort does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629793/
https://www.ncbi.nlm.nih.gov/pubmed/37137277
http://dx.doi.org/10.1093/rheumatology/kead179
work_keys_str_mv AT esperancaalmeidadiogo doesthehalocountontemporalandaxillaryultrasoundpredicttimetorelapseingiantcellarteritis
AT smithkate doesthehalocountontemporalandaxillaryultrasoundpredicttimetorelapseingiantcellarteritis
AT sarkerborshaa doesthehalocountontemporalandaxillaryultrasoundpredicttimetorelapseingiantcellarteritis
AT barrandrew doesthehalocountontemporalandaxillaryultrasoundpredicttimetorelapseingiantcellarteritis
AT wakefieldrichardj doesthehalocountontemporalandaxillaryultrasoundpredicttimetorelapseingiantcellarteritis
AT mackiesarahl doesthehalocountontemporalandaxillaryultrasoundpredicttimetorelapseingiantcellarteritis